Targeting Glioma Stem Cells by Functional Inhibition of Dynamin 2: A Novel Treatment Strategy for Glioblastoma

Rodney Luwor, Andrew P. Morokoff, Stephanie Amiridis, Giovanna D’Abaco, Lucia Paradiso, Stanley S. Stylli, Hong P.T. Nguyen, Mark Tarleton, Kelly A. Young, Terence J. O’Brien, Phillip J. Robinson, Megan Chircop, Adam McCluskey, Nigel C. Jones

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)


Glioma stem cells (GSCs) play major roles in drug resistance, tumour maintenance and recurrence of glioblastoma. We investigated inhibition of the GTPase dynamin 2 as a therapy for glioblastoma. Glioma cell lines and patient-derived GSCs were treated with dynamin inhibitors, Dynole 34-2 and CyDyn 4-36. We studied about cell viability, and GSC neurosphere formation in vitro and orthotopic tumour growth in vivo. Dynamin inhibition reduced glioblastoma cell line viability and suppressed neurosphere formation and migration of GSCs. Tumour growth was reduced by CyDyn 4-36 treatment. Dynamin 2 inhibition therefore represents a novel approach for stem cell-directed Glioblastoma therapy.

Original languageEnglish
Pages (from-to)144-155
Number of pages12
JournalCancer Investigation
Issue number3
Publication statusPublished - 16 Mar 2019


  • Cancer biology
  • Cancer stem cells
  • Dynamin
  • Glioblastoma
  • Invasion

Cite this